The respiratory tract has been used to deliver biologically active chemicals into the human body for centuries. However, the lungs are complex in their anatomy and physiology, which poses challenges to drug delivery. Inhaled formulations are generally more sophisticated than those for oral and parenteral administration. Pulmonary drug development is therefore a highly specialized area because of its many unique issues and challenges. Rapid progress is being made and offers novel solutions to existing treatment problems. Advances in Pulmonary Drug Delivery highlights the latest developments in this field.
Table of Contents
Chapter 1: Inhaled proteins and peptides.
Chapter 2: Inhaled insulin: More compelling than ever.
Chapter 3: Inhaled therapeutic siRNA for the treatment of respiratory diseases.
Chapter 4: New molecules to treat asthma and COPD.
Chapter 5: Inhaled anti-cancer agents.
Chapter 6: Inhaled countermeasures for respiratory tract viruses.
Chapter 7: Pulmonary delivery of antibiotics for respiratory infections.
Chapter 8: Inhaled liposomes.
Chapter 9: Inhaled traditional Chinese medicine for respiratory diseases.
Chapter 10: Bronchoprovocation tests for evaluation of drug efficacy in asthma.
Philip Chi Lip Kwok, BPharm(Hons), PhD, is an assistant professor at the Department of Pharmacology and Pharmacy, The University of Hong Kong. He has 45 publications and two patents in respiratory drug delivery and is an editorial board member of the Journal of Aerosol Medicine and Pulmonary Drug Delivery. He also co-hosted and chaired the inaugural Inhalation Asia conference in Hong Kong in 2013.
Hak-Kim Chan, PhD, DSc, Professor in Pharmaceutics, is leading the Advanced Drug Delivery Group and Respiratory Disease Theme at the Faculty of Pharmacy, University of Sydney. His research focuses on inhalation drug delivery, ranging from particle engineering by novel processes, aerosol formulation and inhaler designs to scintigraphic imaging of lung deposition and clinical outcomes, with over 350 publications in the field.